About Regis Technologies
Regis Technologies is a Healthcare company based in Morton Grove (United States) founded in 1956, and was acquired by Esteve in July 2025. It offers CDMO and bioanalytical services for APIs and Highly potent APIs and proprietary chromatography products for chiral applications. The company has 107 employees. Its chief executive, as recorded, is Louis Glunz IV. Regis Technologies offers products and services including Custom API Development, cGMP Manufacturing, Chromatography Columns, and Specialty Reagents. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Instruments and Chromatography. Its legal entity is REGIS TECHNOLOGIES INC. Its competitors include ChromaTan, Sepax Technologies and Semba Biosciences; 3 of its 3 listed competitors have raised funding.
Company details
Regis Technologies offers synthesis, analytical and separation services to pharma companies to advance active pharmaceutical ingredient (API) and intermediates from initial process development and scale-up phases to final validation and commercial manufacturing. The company has special expertise in Supercritical Fluid Chromatography (SFC) and chiral compound development and separation. The companys service portfolio includes custom API and HPAPI manufacturing, analytical method development, cGMP non-GMP SFC separations, process research services (synthetic route modification and process validation) and quality control services. The company offers proprietary chromatography products with a special chiral emphasis.
- Headquarters Morton Grove, United States
- Employees 107
- Stage Acquired
- SectorsHealthcare
- Website registech.com
- Social LinkedIn X
- Acquired by Esteve (Jul 2025)
- Legal Name Regis Technologies Inc
- Latest Funding Round$229.74K (USD), Grant
Jul 2021
- InvestorsFirst AmBank
& 2 more
- Employee Count107
- Acquired byEsteve
(Jul 2025)
Products & Services of Regis Technologies
Regis Technologies offers a comprehensive portfolio of products and services, including Custom API Development, cGMP Manufacturing, Chromatography Columns, and Specialty Reagents.
Service for developing and manufacturing pharmaceutical APIs.
Compliance-focused manufacturing for clinical and commercial APIs.
Specialized columns for HPLC and SFC separations.
Reagents for ion pairing and derivatizing in analysis.
Funding Insights of Regis Technologies
- Total Rounds 2
- Last Round Grant — $229,741
- First Round $3M
(Dec 2005)
- Investors Count 2
All 2 funding rounds of Regis Technologies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2021 | $229,741 | Grant | – | – | |
| Dec 2005 | $3M | Debt – Conventional | – | – |
3 investors in total: 3 institutional.
Investors in Regis Technologies
Regis Technologies has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include First AmBank, HHS and Esteve.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Commercial banking services are provided to businesses and individuals. | 1974 | firstambank.com | Elk Grove Village, United States | |
Therapies for chronic pain treatment are developed by Esteve. | 1929 | esteve.com | Barcelona, Spain |
Investor details for Regis Technologies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Regis Technologies
32 people are tracked at Regis Technologies (7 in leadership, 25 in team); the tracked headcount is 107.
| Name | Role | Group |
|---|---|---|
Louis Glunz IV | CEO & President | Leadership |
Richard Myer | Chief Business Development Officer | Leadership |
Burr Martin | COO CFO | Leadership |
Alan Henderson | Vice President, Chemistry | Leadership |
Eric Buck | Head Of Process Safety | Leadership |
Siead Zegar | Director, Technical Operations And Process Chemistry | Leadership |
Burrous Martin | COO CFO | Leadership |
Michael Kruk | Project Manager | Team |
Douglas Yarbrough | Research Scientist - Process Chemistry | Team |
Melissa Wilcox | Global Sales And Market Development Manager | Team |
Chris Tokar | Process Development & Research Chemist III | Team |
Panagiotis Alexakos | Research Scientist - Process Chemistry | Team |
James Letzkus | Quality Assurance Associate | Team |
Judy Koppe | QC Chemist | Team |
Katie Kretschmer | Quality Assurance Associate | Team |
Samantha Wijeweera | QC Chemist 2 | Team |
Sophia Imeroni | Business Development Associate | Team |
Charvi Payghode | Environment, Health And Safety Manager | Team |
James Colegrove | Maintenance Technician | Team |
Julius Jackson | Production Specialist | Team |
12 more people are available in the full profile.
Complete people profiles for Regis Technologies
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Regis Technologies
4 dated milestones of Regis Technologies across 69 years, from founding to its latest funding, stage changes and deals.
- Founded Regis Technologies is founded.
- Funding First funding round of $3.0M.
- Funding Latest funding round, Grant, of $230K.
- Exit Acquired by Esteve.
Competitors of Regis Technologies
Regis Technologies has 3 listed competitors in our database, 3 of them funded. They include ChromaTan, Sepax Technologies and Semba Biosciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| chromatan.com | 2009 | State College, United States | $5.32M | Continuous countercurrent tangential chromatography separation technology is developed. | ||
| sepax-tech.com | 2002 | Newark, United States | $109.24M | 57 | Solutions for chromatographic biomolecular separation are developed and provided. | |
| sembabio.com | 2005 | Madison, United States | $5.85M | Provider of systems for molecular separation based on simulated moving bed chromatography (SMBC) |
Detailed competitors of Regis Technologies
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Regis Technologies
The website of Regis Technologies (registech.com) receives about 7.1K visits a month.
- Monthly visits7.1K
▲ 50.3% vs previous month
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Regis Technologies (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Regis Technologies
Complete news archive for Regis Technologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Regis Technologies
Regis Technologies was founded in 1956 and raised its 1st funding round 49 years after it was founded.
Regis Technologies is headquartered in Morton Grove, United States. It is registered at Morton Grove, Illinois, United States.
Louis Glunz IV is the CEO of Regis Technologies, as recorded in our data.
Regis Technologies has 107 employees.
Regis Technologies offers synthesis, analytical and separation services to pharma companies to advance active pharmaceutical ingredient (API) and intermediates from initial process development and scale-up phases to final validation and commercial manufacturing. The company has special expertise in Supercritical Fluid Chromatography (SFC) and chiral compound development and separation. The companys service portfolio includes custom API and HPAPI manufacturing, analytical method development, cGMP non-GMP SFC separations, process research services (synthetic route modification and process validation) and quality control services. The company offers proprietary chromatography products with a special chiral emphasis.
Regis Technologies's top competitors include ChromaTan, Sepax Technologies and Semba Biosciences.
Regis Technologies offers Custom API Development, cGMP Manufacturing, Chromatography Columns, and Specialty Reagents.
Regis Technologies has 3 investors. Key investors include First AmBank, HHS, and Esteve.
Regis Technologies operates through Regis Technologies Inc.
Yes. Regis Technologies was acquired by Esteve in July 2025.